Article
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
PloS one - 1 Jan 2013
Bradshaw-Pierce Erica L, Pitts Todd M, Kulikowski Gillian, Selby Heather, Merz Andrea L, Gustafson Daniel L, Serkova Natalie J, Eckhardt S Gail, Weekes Colin D
Abstract excerpt
PURPOSE: The PI3K/AKT/mTOR pathway is frequently dysregulated in cancers and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways. As such, we sought to determine the ability of the mTOR inhibitor everolimus to potentiate the antitumor effects of irinotecan in colorectal cancer (CRC). EXPERIMENTAL DESIGN: The combinatorial effects of everolimus and irinotecan were evaluated in vitro...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.